A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.

Boryung

Status: Enrolling

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Second and later-line palliative chemotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT07263178

BR-CPT-OS-402

Details and patient eligibility

About

This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have signed the informed consent after receiving information about the purpose and method of this study.
• Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.
• Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).
• Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.

Exclusion criteria

• Female patients who are pregnant, have childbearing potential, or are breastfeeding.
• Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
• Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.